# Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.

> **NCT04721821** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 7807 (actual)

## Conditions studied

- Arthritis Rheumatoid

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT04721821
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-22
- **Primary completion:** 2021-11-29
- **Final completion:** 2021-11-29
- **Target enrollment:** 7807 (ACTUAL)
- **Last updated:** 2024-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04721821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04721821, "Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04721821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*